The Hospital Value-Based Purchasing Program did not result in meaningful improvements in clinical process or patient experience measures during its first four years, because performance improved similarly for hospitals not exposed to the program, according to a study reported last week in the New England Journal of Medicine. The program was associated with reduced mortality among patients admitted for pneumonia, but not among patients admitted for heart attack or heart failure. Nancy Foster, AHA vice president for quality and patient safety policy, said the findings “should not be surprising for two important reasons. First, the measures used in the VBP program, especially those used in the first few years, had been publicly reported for several years. Many of the improvements that could be achieved had already occurred. Second, hospitals view the inclusion of a measure in the Hospital VBP program as a strong signal from Medicare that high performance on the measure is important. Thus, hospitals seek to achieve high levels of performance on the chosen measures regardless of whether they are subject to a payment penalty or not.”

Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…